AIM

AIM ImmunoTech Inc. (AIM) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.8 (Weak)

AIM does not show evidence of durable brand, patent, or regulatory franchise power in the provided metrics, so it lacks a clear source of pricing power versus peers.

Negative ROIC and ROCE imply any intangible advantage is not translating into economic returns, which is weaker than peers with proven monetization of proprietary assets.

No 5-year margin or growth persistence is provided, so there is no evidence of a protected customer franchise that would sustain retention over a 5–10 year horizon.

Compared with peers that can defend pricing through recognized IP or regulated positioning, AIM appears more replicable and less able to convert intangibles into durable margins.

Switching Costs

Score:

The very negative TTM ROIC suggests customers are not locked in by high switching frictions that would preserve returns versus peers.

No evidence of recurring-contract stickiness, embedded workflow dependence, or integration depth is provided, so retention appears weak relative to stronger software or platform peers.

The absence of positive operating profitability indicates AIM is not capturing the pricing power that usually accompanies meaningful switching costs.

Compared with peers that benefit from mission-critical products or high implementation costs, AIM appears easier to replace and therefore less durable.

Network Effects

Score:

The provided data do not indicate user, data, or ecosystem feedback loops, so there is no visible self-reinforcing demand advantage versus peers.

Negative capital returns argue against a network structure that is currently monetizing scale into stronger economics.

No evidence of platform dependency, multi-sided participation, or increasing returns is provided, which keeps the moat score near the bottom of the range.

Relative to peers with clear network flywheels, AIM shows no sign of compounding advantage from connected users or data.

Cost Advantage

Score:

AIM’s negative ROIC and ROCE indicate it is not operating with a cost structure that converts into superior unit economics versus peers.

The extremely low asset turnover suggests assets are not being used efficiently enough to support a durable cost edge.

No evidence of scale purchasing, process superiority, or structural input-cost advantage is provided, so any cost benefit appears absent or unproven.

Compared with peers that can underprice competitors while still earning acceptable returns, AIM does not show a defensible cost advantage.

Efficient Scale

Score:

The available metrics do not show that AIM serves a niche where market size naturally limits the number of viable competitors, which is the core of efficient scale.

Negative returns suggest the business is not extracting monopoly-like economics from a constrained market structure versus peers.

No evidence of regulated scarcity, exclusive access, or capacity-limited dominance is provided, so efficient scale is not visible.

Compared with peers that operate in tightly bounded markets with few rational competitors, AIM does not appear to benefit from structural scale protection.

Overall Score

Score:

AIM shows no clear evidence of durable moat drivers in the provided data, and the negative ROIC/ROCE plus very low asset turnover point to weak pricing power and poor conversion of any advantages into returns versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on AIM ImmunoTech Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →